Summary of Study ST000138

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR000123. The data can be accessed directly via it's Project DOI: 10.21228/M8PC7J This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST000138
Study TitleTargeted LC MS of acylcarnitines: TLCMS
Study SummaryAcylcarnitines (panel of 66 quantitated acylcarnitines) analyzed by LC/MS/MS using flow injection analysis with electrospray ionization
Institute
University of Florida
DepartmentPharmacotherapy and Translational Research
Last NameCooper-DeHoff
First NameRhonda
Emaildehoff@cop.ufl.edu
Submit Date2015-01-08
Raw Data AvailableYes
Raw Data File Type(s)d
Uploaded File Size1.3 G
Analysis Type DetailLC-MS
Release Date2016-06-18
Release Version1
Rhonda Cooper-DeHoff Rhonda Cooper-DeHoff
https://dx.doi.org/10.21228/M8PC7J
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR000123
Project DOI:doi: 10.21228/M8PC7J
Project Title:A targeted pharmacometabolomic investigation of the acylcarnitine pathway and incident impaired fasting glucose (IFG)
Institute:University of Florida
Department:Pharmacotherapy and Translational Research
Last Name:Cooper-DeHoff
First Name:Rhonda
Email:dehoff@cop.ufl.edu

Subject:

Subject ID:SU000157
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Human Inclusion Criteria:Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG.
Human Exclusion Criteria:Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study.
Species Group:Mammals

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Gender Race
SA007499PE0077f asian
SA007500PE0005f black
SA007501PE0403f black
SA007502PE0380f black
SA007503PF0436f black
SA007504PE0358f black
SA007505PE0422f black
SA007506PE0423f black
SA007507PE0488f black
SA007508PE0492f black
SA007509PE0455f black
SA007510PE0438f black
SA007511PE0433f black
SA007512PE0346f black
SA007513PE0332f black
SA007514PE0251f black
SA007515PE0268f black
SA007516PE0243f black
SA007517PE0240f black
SA007518PE0224f black
SA007519PE0285f black
SA007520PF0463f black
SA007521PF0448f black
SA007522PE0330f black
SA007523PE0317f black
SA007524PE0310f black
SA007525PE0292f black
SA007526PE0494f black
SA007527PR0449f black
SA007528PF0093f black
SA007529PF0146f black
SA007530PF0080f black
SA007531PF0079f black
SA007532PF0078f black
SA007533PF0156f black
SA007534PF0165f black
SA007535PF0184f black
SA007536PF0201f black
SA007537PF0181f black
SA007538PF0228f black
SA007539PF0169f black
SA007540PR0300f black
SA007541PF0305f black
SA007542PE0536f black
SA007543PE0540f black
SA007544PE0517f black
SA007545PF0357f black
SA007546PF0361f black
SA007547PF0020f black
SA007548PF0330f black
SA007549PF0060f black
SA007550PF0048f black
SA007551PF0315f black
SA007552PF0044f black
SA007553PE0219f black
SA007554PE0331f black
SA007555PF0528f black
SA007556PE0114f black
SA007557PE0216f black
SA007558PF0543f black
SA007559PE0086f black
SA007560PE0092f black
SA007561PF0524f black
SA007562PE0128f black
SA007563PE0143f black
SA007564PE0148f black
SA007565PF0507f black
SA007566PE0138f black
SA007567PE0137f black
SA007568PE0072f black
SA007569PE0071f black
SA007570PE0037f black
SA007571PE0040f black
SA007572PE0032f black
SA007573PE0028f black
SA007574PE0019f black
SA007575PE0022f black
SA007576PE0042f black
SA007577PE0045f black
SA007578PE0064f black
SA007579PE0068f black
SA007580PE0062f black
SA007581PE0059f black
SA007582PE0055f black
SA007583PE0149f black
SA007584PF0539f black
SA007585PE0188f black
SA007586PE0186f black
SA007587PE0181f black
SA007588PE0172f black
SA007589PE0191f black
SA007590PE0196f black
SA007591PE0205f black
SA007592PE0203f black
SA007593PF0494f black
SA007594PE0169f black
SA007595PE0187f black
SA007596PE0161f black
SA007597PE0168f black
SA007598PF0424f black_hisp
Showing page 1 of 4     Results:    1  2  3  4  Next     Showing results 1 to 100 of 370

Collection:

Collection ID:CO000141
Collection Summary:At baseline and after completion of atenolol treatment, blood samples were collected and spun. Serum and plasma fractions were stored at -80C. 200 uL of plasma were aliquoted for metabolomics analyses. Sample Type: Blood serum Volume Collected: 200 uL
Sample Type:Blood

Treatment:

Treatment ID:TR000159
Treatment Summary:Atenolol was initiated at 50mg, and titrated to 100mg, based on BP > 120/70 mmHg and tolerability. Blood samples were collected prior to initiation of atenolol treatment and after at least 6 weeks on the final dose. Blood samples were spun and serum and plasma fractions stored at -80C. Treatment: Intervention Treatment Compound: Atenolol Treatment Dose: 50mg titrated to 100mg based on BP and tolerability Treatment Dose Duration: Minimum of 6 weeks

Sample Preparation:

Sampleprep ID:SP000154
Sampleprep Summary:-
Sampleprep Protocol Filename:Acylcarnitines_LCMSProtocol_SBMRI_ForSECIM_111714.docx

Combined analysis:

Analysis ID AN000220
Analysis type MS
Chromatography type Reversed phase
Chromatography system Agilent 1290 Infinity
Column Waters Acquity BEH C18 (100 x 2mm,1.7um)
MS Type ESI
MS instrument type Triple quadrupole
MS instrument name Agilent 6490 QQQ
Ion Mode POSITIVE
Units uM

Chromatography:

Chromatography ID:CH000152
Instrument Name:Agilent 1290 Infinity
Column Name:Waters Acquity BEH C18 (100 x 2mm,1.7um)
Chromatography Type:Reversed phase

MS:

MS ID:MS000171
Analysis ID:AN000220
Instrument Name:Agilent 6490 QQQ
Instrument Type:Triple quadrupole
MS Type:ESI
Ion Mode:POSITIVE
  logo